{"filing":{"accession_number":"0001193125-26-290447","cik":"0001810182","ticker":"ALXO","company_name":"ALX ONCOLOGY HOLDINGS INC","form":"8-K","filing_date":"2026-06-30","report_date":null,"primary_document":"alxo-20260629.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1810182/000119312526290447/alxo-20260629.htm"},"events":[{"id":15035,"run_id":13415,"accession_number":"0001193125-26-290447","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.9,"summary":"ALX Oncology appointed Scott Garland as Chairman of the Board (effective June 29, 2026) and Michael Listgarten as General Counsel (effective immediately), representing a significant governance transition. Corey Goodman, co-founder, stepped down as Chairman after more than a decade of leadership.","company_name":"ALX ONCOLOGY HOLDINGS INC","ticker":"ALXO","filing_date":"2026-06-30","form":"8-K","submitted_at":null,"items":[{"id":12649,"accession_number":"0001193125-26-290447","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The Item 5.02 disclosure centers on two executive appointments effective June 30, 2026: Scott Garland as Chairman of the Board (succeeding co-founder Corey Goodman) and Michael Listgarten as General Counsel. While Goodman's resignation is mentioned, the principal action disclosed in the press release and the filing is the appointment of new leadership. The appointment of a new Chairman is material to investors as it represents a significant governance transition at a clinical-stage biotech company advancing late-stage pipeline candidates.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-01T02:20:56.628110+00:00","company_name":"","ticker":null,"filing_date":""},{"id":12650,"accession_number":"0001193125-26-290447","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The filing discloses the appointment of Scott Garland as Chairman of the Board and Michael Listgarten as General Counsel, effective immediately. While the press release also mentions Corey Goodman stepping down as Chairman after more than a decade of foundational leadership, the principal disclosed action centers on the two new appointments to senior leadership roles. The appointment of a new Chairman is a material governance event affecting the registrant's leadership structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-01T02:20:56.628110+00:00","company_name":"","ticker":null,"filing_date":""},{"id":12651,"accession_number":"0001193125-26-290447","item_number":"8.01","item_title":"Other Events.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The filing discloses the appointment of Scott Garland as Chairman of the Board effective June 29, 2026, and Michael Listgarten as General Counsel, both effective immediately. While Dr. Corey Goodman's resignation as Chairman is mentioned, the principal disclosed action centers on the appointments of two executives to significant leadership roles. The press release emphasizes Garland's appointment as the lead event (\"Appoints Scott Garland as Chairman\") and highlights his 30+ years of biopharmaceutical industry experience and prior board service since November 2022.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-01T02:20:56.628110+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":12649,"accession_number":"0001193125-26-290447","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The Item 5.02 disclosure centers on two executive appointments effective June 30, 2026: Scott Garland as Chairman of the Board (succeeding co-founder Corey Goodman) and Michael Listgarten as General Counsel. While Goodman's resignation is mentioned, the principal action disclosed in the press release and the filing is the appointment of new leadership. The appointment of a new Chairman is material to investors as it represents a significant governance transition at a clinical-stage biotech company advancing late-stage pipeline candidates.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-01T02:20:56.628110+00:00","company_name":"ALX ONCOLOGY HOLDINGS INC","ticker":"ALXO","filing_date":"2026-06-30"},{"id":12650,"accession_number":"0001193125-26-290447","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The filing discloses the appointment of Scott Garland as Chairman of the Board and Michael Listgarten as General Counsel, effective immediately. While the press release also mentions Corey Goodman stepping down as Chairman after more than a decade of foundational leadership, the principal disclosed action centers on the two new appointments to senior leadership roles. The appointment of a new Chairman is a material governance event affecting the registrant's leadership structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-01T02:20:56.628110+00:00","company_name":"ALX ONCOLOGY HOLDINGS INC","ticker":"ALXO","filing_date":"2026-06-30"},{"id":12651,"accession_number":"0001193125-26-290447","item_number":"8.01","item_title":"Other Events.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The filing discloses the appointment of Scott Garland as Chairman of the Board effective June 29, 2026, and Michael Listgarten as General Counsel, both effective immediately. While Dr. Corey Goodman's resignation as Chairman is mentioned, the principal disclosed action centers on the appointments of two executives to significant leadership roles. The press release emphasizes Garland's appointment as the lead event (\"Appoints Scott Garland as Chairman\") and highlights his 30+ years of biopharmaceutical industry experience and prior board service since November 2022.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-01T02:20:56.628110+00:00","company_name":"ALX ONCOLOGY HOLDINGS INC","ticker":"ALXO","filing_date":"2026-06-30"}]}